IOL Chemicals Q1 FY27 Revenue Surges 37.1% to ₹756.3 Cr, PAT Jumps 89.9%
IOL Chemicals reported record Q1 FY27 results with revenue up 37.1% to ₹756.3 crore and PAT up 89.9% to ₹64.5 crore. Pharmaceuticals revenue grew 43% YoY, driven by non-Ibuprofen APIs. Chemicals revenue increased 29% YoY. Exports contributed 28.5% of revenue. Clopidogrel API received NMPA approval in China.
The announcement details strong financial results with significant growth metrics and positive business segment performance, including new market approvals, which are material to investors.
The company reported record quarterly performance with significant year-on-year growth in revenue, EBITDA, and PAT, alongside improved margins and positive commentary on business drivers and future outlook.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) announced its unaudited financial results for the quarter ended 30th June 2026, reporting a record quarterly performance with its highest-ever revenue.
Standalone revenue from operations for Q1 FY27 stood at ₹756.3 crore, marking a significant year-on-year increase of 37.1% from ₹551.7 crore in Q1 FY26. EBITDA grew by 60.7% to ₹111.7 crore, with the EBITDA margin expanding to 14.6% from 12.4%. Profit After Tax (PAT) saw a substantial jump of 89.9% to ₹64.5 crore, compared to ₹34.0 crore in the same period last year. PAT margin improved to 8.4% from 6.1%.
Mr. Vikas Gupta, Joint Managing Director, commented that the performance was achieved despite geopolitical uncertainties, supply chain disruptions, and inflationary pressures. Growth and margin expansion were driven by improved capacity utilization, a favorable product mix, and operational efficiencies. The Pharmaceuticals business was a key growth driver, with revenue increasing 43% year-on-year and EBIT growing 72% year-on-year. Non-Ibuprofen products contributed 43% of Pharma revenue, up from 36% a year ago, with strong demand for Paracetamol, Pantoprazole, Metformin, and Fenofibrate APIs. Paracetamol capacity utilization improved to 65%.
The Chemicals business delivered 29% year-on-year revenue growth and 193% year-on-year EBIT growth, attributed to operational efficiencies, raw material procurement, better realisations, and higher exports. Overall exports contributed 28.5% of revenue, up from 24.4% in Q1 FY26. Additionally, IOLCP's Clopidogrel API received NMPA approval in China.
Looking ahead, the company plans to focus on scaling its portfolio, improving product mix, enhancing capacity utilization, and expanding its presence in value-added APIs and specialty chemicals.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.